CSIMarket Company Name, Ticker, Suppliers, else..
 
Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)
 

Aurinia Pharmaceuticals Inc's Suppliers Performance

AUPH's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
AUPH Costs vs Sales of Suppliers Growth Aurinia Pharmaceuticals Inc's cost of sales deteriorated by -7.87 % year on year, sequentially cost of sales grew by 0.77 % in Q2.

• More on AUPH Suppliers



Aurinia Pharmaceuticals Inc's cost of sales deteriorated by -7.87 % year on year, sequentially cost of sales grew by 0.77 % in Q2.

• More on AUPH Suppliers




Aurinia Pharmaceuticals Inc's Comment on Supply Chain


Aurinia sources raw materials for the manufacture of voclosporin and has maintained sufficient inventory and manufacturing capacity to meet forecasted demand. In December 2020, Aurinia entered into a manufacturing services agreement with Lonza to construct the Monoplant, a dedicated facility for voclosporin production, which commenced operations in June 2023. Aurinia pays Lonza a quarterly fixed facility fee for exclusive use of the Monoplant through March 31, 2030. Catalent Pharma Solutions serves as the sole supplier for the preparation of voclosporin capsules under a supply agreement, and Aurinia anticipates continuing this contract manufacturing relationship. For blistering and packaging of LUPKYNIS commercial cartons for the U.S. market, Aurinia utilizes a sole supplier under a supply agreement and expects no disruptions in these services.

Aurinia Pharmaceuticals Inc's Comment on Supply Chain


Aurinia sources raw materials for the manufacture of voclosporin and has maintained sufficient inventory and manufacturing capacity to meet forecasted demand. In December 2020, Aurinia entered into a manufacturing services agreement with Lonza to construct the Monoplant, a dedicated facility for voclosporin production, which commenced operations in June 2023. Aurinia pays Lonza a quarterly fixed facility fee for exclusive use of the Monoplant through March 31, 2030. Catalent Pharma Solutions serves as the sole supplier for the preparation of voclosporin capsules under a supply agreement, and Aurinia anticipates continuing this contract manufacturing relationship. For blistering and packaging of LUPKYNIS commercial cartons for the U.S. market, Aurinia utilizes a sole supplier under a supply agreement and expects no disruptions in these services.







AUPH's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Aurinia Pharmaceuticals Inc 2,215.93 311.51 314.11 128
SUBTOTAL 0.00 0.00 0.00 -


Sources: Aurinia Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aurinia Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.